Best Practice Tips for Overcoming Obstacles in Biomarker Development

Pharma IQ

How can we overcome the latest challenges in Biomarker Development? Birgitte Søgaard, Divisional Director for Clinical Pharmacology and Translational Medicine at H Lundbeck A/S, discusses with Helen Winsor from Pharma IQ, the key challenges in this area, in particular the need for cost-efficiency. She outlines some of the solutions used by her organisation to address the obstacles commonly faced during Phase I, such as successful biomarker development, improving trial design and mi...
To continue reading this story get free access